Bioequivalence study of levofloxacin tablets in healthy Indian volunteers using HPLC

Abstract

An improved HPLC method was developed and validated for the determination of concentration of levofloxacin (CAS 100986-85-4) in human plasma. This paper is an attempt to compare the bioavailability of two levofloxacin tablet formulations (reference and test) containing 500 mg of levofloxacin. Both the formulations were administered orally as a single dose, separated by a washout period of 1 week. The HPLC method was validated by examining the precision and accuracy for the inter-day and intra-day runs in a linear concentration range of 0.10–10.00 μg/ml. Bioequivalence of two formulations were determined in 12 healthy, Indian, male volunteers in a single-dose, two-period, two-sequence, two-treatment crossover study. The content of levofloxacin in plasma was determined using HPLC with UV detection.

The formulations were compared using the following pharmacokinetic parameters: area under the plasma concentration-time curve (AUC_0–t), area under the plasma concentration-time curve from zero to infinity (AUC_0–∞), peak plasma concentration (C_max), and time to reach peak plasma concentration (t_max). The results indicated that there were no statistically significant differences (P > 0.05) between the logarithmically transformed AUC_0–∞ and C_max values of the test and reference formulations. The 90% confidence interval for the ratio of the logarithmically transformed AUC_0–t, AUC_0–∞ and C_max were within the bioequivalence limit of 0.8–1.25 and the relative bioavailability of the test formulation was 99.98% of that of the reference formulation.

Key words

Antibacterial - CAS 100986-85-4 - HPLC-UV - Levofloxacin - Pharmacokinetics

• References

• 1 Tanaka M, Kurata T, Fujisawa C, Oshima Y, Aoki H, Okazaki O et al. Mechanistic study of inhibition of levofloxacin absorption by aluminium hydroxide. Antimicrob Agents Chemother. 1993; 37: 2173-78
• 2 Eliopoulos GM, Eliopoulos CT, Hoope DC, Wolfson JS editors. In: Quinolone antibacterial agents. Washington (DC): American Society for Microbiology; 1993: 161-193
• 3 Shen LL, Hoope DC, Wolfson JS editors. In: Quinolone antibacterial agents. Washington (DC): American Society for Microbiology; 1993: 77-95
• 4 Ungerstedt U. Microdialysis: principles and applications for studies in animals and man. J Intern Med. 1991; 230: 365
• 5 Müller M. Microdialysis in clinical drug delivery studies. Drug Deliv Rev. 2000; 45: 255-269
• 6 Guenter SG, Iven H, Boos C, Bruch HP, Muhl E. Pharmacokinetics of levofloxacin during continuous venovenous he-modiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy. 2002; 22: 175-8
• 7 Djabarouti S, Boselli E, Allaouchiche B, Ba B, Nguyen AT, Gordien JM et al. Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B. 2004; 799: 165-72
• 8 Wong FA, Juzwin SJ, Flor SC. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J Pharm Biomed Anal. 1997; 765-71
• 9 Park DJ, Phapale PB, Jang IJ, Cui S, Moon BJ, Kim JE et al. An improved UPLC method for rapid analysis of levofloxacin in human plasma. Chromatographia. 2008; 68: 187-92
• 10 Gao X, Yao G, Guo N, An F, Guo X. A simple and and rapid high performance liquid chromatography method to determine levofloxacin in human plasma and its use in a bioequivalence study. Drug Discov Ther. 2007; 2: 136-40
• 11 Liang H, Kays MB, Sowinski KM. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2002; 772: 53-63
• 12 Fish DN, Chow AT. The clinical pharmacokinetic of levofloxacin. Clin Pharmacokinet. 1997; 32: 101-19
• 13 Siewert S. Validation of a levofloxacin assay in plasma and dialysate for pharmacokinetic studies. J Pharm Biomed Anal. 2006; 41: 1360-62
• 14 Conte Jr JE, Golden JA, McIver M, Zurlinden E. Intrapul-monary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents. 2006; 28: 114-21
• 15 Hauschke D, Steinijans V, Diletti E. A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 30: 37-43
• 16 Schulz HU, Steinijans VW. Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol Ther Toxicol. 1992; 30: 51-6
• 17 Farolfi M, Power JD, Rescigno A. On the determination of bioequivalence. Pharmacol Res. 1999; 39: 1-4
• 18 Das A, Bhaumik U, Chakraborty US, Sarkar AK, Ghosh A, Bose A et al. Comparative bioavailability study of amisul-pride tablets in healthy indian volunteers. Arzneimittelforschung. 2009; 59 (4) 166-70
• 19 Mandai U, Ganesan M, Pal TK, Jayakumar M, Chattaraj TK, Ray K et al. bioequivalence study of rabeprazole sodium on healthy human subjects. J Ind Med Assoc. 2004; b 102 (1) 26-30
• 20 U. S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for orally Administered Drug Products – General Considerations. Rockville (MD): Center for Drug Evaluation and Research; 2000.
• 21 Committee for Proprietary Medicinal Products (CPMP). Note for Guidance: Investigation of Bioavailability and Bioequivalence. London: Working Party on the Efficacy of the Medicinal Products; 1991.
• 22 European Agency for the Evaluation of Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98; 2002.
• 23 Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther. 1994; 62: 41-55
• 24 Shah VP, Midha KK, Sing S. Analytical method validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet. 1992; 16: 249-55
• 25 Ritschel WA Drug Intelligenc. In: Handbook of Basic Pharmacokinetics. 4^th ed. Hamilton: Hamilton Press; 1992: 588